BIO Early-Stage Resources Hub
Access a range of exclusive resources, including cost-saving programs, educational webinars and stay up-to-date with the latest BIO Emerging Companies Section (ECS) events with our comprehensive resource center, designed to empower early-stage companies and help them thrive.
SBIR (4)
SHARE
PDF
PSC Biotech: Grant Writing White Paper
FLIP
SHARE
A white paper on regulatory grant writing, best practices for developing proposals, success factors, and tackling grant writing challenges.
FLIP
SHARE
PDF
SBIR Application Key Decision Points Flowchart
FLIP
SHARE
A grant application flowchart from start to finish. Includes decision points and scenarios to help determine which agencies and grants to apply to.
FLIP
SHARE
PDF
BIO Office Hours: Grant Writing Slides
FLIP
SHARE
A PowerPoint presentation on the grant application process. An overview of how to identify opportunities, how to compose a proposal, and project management tips.
FLIP
Raising Investor Capital (2)
SHARE
PDF
BIO Large Biopharma Therapeutic Focus Guide
FLIP
SHARE
This resource provides guidance to assist early-stage companies in identifying potential large biopharma partners.
FLIP
SHARE
PDF
BIO Large Biopharma Therapeutic Focus Resource
FLIP
SHARE
This resource provides guidance to assist early-stage companies in identifying potential large biopharma partners.
FLIP
Capital Formation Policy Issues (15)
SHARE
PDF
BIO Issue Brief: Committee on Foreign Investment in the United States (CFIUS) (9/22/2022)
FLIP
SHARE
An overview of CFIUS and how the Administration’s focus on protecting the U.S. Biotech Industry could cause unintentional harm by impeding foreign investment and collaborations.
FLIP
SHARE
PDF
Minimum Pricing Increments, Access Fees, and Transparency of Better Priced Orders (3/30/2023)
FLIP
SHARE
Comments on proposed rule to adapt a variable minimum pricing increments for the quoting and trading of NMS stocks, reduce access fee caps, and enhance transparency of better priced orders.
FLIP
SHARE
PDF
FTC Comment Letter: Request for Comment on Pharmaceutical Task Force, Project No. P212900 (6/13/2021)
FLIP
SHARE
Comments in response to Federal Trade Commission’s Pharmaceutical Task Force’s request for public comment.
FLIP
SHARE
PDF
SEC Comment Letter: Order Competition Rule (3/30/2023)
FLIP
SHARE
Comments on proposed rule to amend regulations governing the national market system (NMS).
FLIP
SHARE
PDF
Statement for the Record: "A Roadmap for Growth: Reforms to Encourage Capital Formation and Investment Opportunities for All Americans" (4/23/2023)
FLIP
SHARE
Statement for the Record to House Financial Services Committee, Subcommittee on Capital Markets.
FLIP
SHARE
PDF
SEC Comment Letter: Request for Comment on Climate Risk Disclosures (6/13/2021)
FLIP
SHARE
PDF
FTC Comment Letter: Request for Information on Merger Enforcement (4/15/2022)
FLIP
SHARE
PDF
SEC Comment Letter: Short Position and Short Activity Reporting (4/25/2022)
FLIP
SHARE
Comments on proposed rule to require money managers to disclose within 14 calendar days after month-end certain gross short positions on companies.
FLIP
SHARE
PDF
Testimony: "The Impact of Consolidation and Monopoly Power on American Innovation" (12/15/2021)
FLIP
SHARE
Testimony of BIO’s Chief Policy Officer before the Senate Subcommittee on Competition Policy, Antitrust, and Consumer Rights on consolidation and monopoly power.
FLIP
SHARE
PDF
Request for Comment on Proposed Amendments to Rules Governing Proxy Voting Advice (12/23/2021)
FLIP
SHARE
PDF
BIO Letter to Senate Banking Cmte: Proposals to Foster Capital Formation and Economic Growth in the Bioeconomy (3/18/2021)
FLIP
SHARE
BIO Letter to Senate Banking Committee in support of proposals to foster capital formation for biotechs.
FLIP
SHARE
PDF
Cybersecurity Risk Management, Strategy, Governance, and Incident Disclosure (5/5/2022)
FLIP
SHARE
Comments on proposed rule to enhance and standardize disclosures regarding cybersecurity risk management, strategy, governance, and incident reporting by public companies.
FLIP
SHARE
PDF
BIO Letter of Support: Short Sale Transparency and Market Fairness Act (7/29/2021)
FLIP
BIO Office Hour Materials (1)
SHARE
PDF
Chubb Cyber Index
FLIP
SHARE
Contains graphs and charts on cyber threat trends. View data on assets affected, annual claims, and more by industry and revenue size.
FLIP
Tax Policy Issues (5)
SHARE
PDF
Talking Points: Impact of Domestic R&D Amortization on the Biotechnology Community (4/21/2023)
FLIP
SHARE
Talking points on the background, impact on the biotechnology community and solution.
FLIP
SHARE
PDF
Letter to House & Senate Leaders: R&D Amortization (6/15/2022)
FLIP
SHARE
BIO, BIO members, and State affiliates urge immediate legislative action to repeal the harmful R&D amortization provision that went into effect in 2022.
FLIP
SHARE
PDF
BIO Tax Priorities Overview (7/6/2023)
FLIP
SHARE
PDF
Letter to House & Senate Leaders: R&D Amortization (5/4/2023)
FLIP
SHARE
BIO and BIO members urge immediate legislative action to repeal the harmful R&D amortization provision that went into effect in 2022.
FLIP
SHARE
PDF
Statement for the Record: "American Ingenuity: Promoting Innovation Through the Tax Code"
FLIP
SHARE
BIO letter to House Small Business Committee outlining 7 tax policy recommendations for supporting biotechs.
FLIP
Industry Analysis (4)
SHARE
PDF
The State of Innovation in Antibacterial Therapeutics
FLIP
SHARE
This report investigates recent investment into antibacterial innovation and the current clinical pipeline that will help bridge the gaps in the antibacterial armamentarium.
FLIP
SHARE
PDF
The State of Innovation in Vaccines and Prophylactic Antibodies for Infectious Diseases
FLIP
SHARE
This report focuses on vaccine innovation and success at the clinical stage, as well as the innovation of prophylactic antibodies in clinical trials.
FLIP
SHARE
PDF
IRA’s Impact on the US Biopharma Ecosystem
FLIP
SHARE
New research released by Vital Transformation (VT) shows that the Inflation Reduction Act (IRA) will stifle the ability of companies to continue research and development across a broad range of therapeutic areas.
FLIP
Explore BIO
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved